复方利血平氨苯蝶啶片治疗原发性高血压有效性及安全性的Meta分析

The efficacy and safety of Compound Rreserpine and Triamterene tablets in the treatment of primary hypertention:a Meta-analysis

目的系统评价复方利血平氨苯蝶啶片(北京降压0号)治疗原发性高血压的有效性和安全性。方法检索PubMed、Cochrane、Web of Science、中国学术期刊全文数据库(CNKI)、维普数据库、万方数据库及百度学术数据库,中文检索词为复方利血平氨苯蝶啶片、降压零号、北京降压0号、高血压,英文检索词为com⁃pound reserpine and triamterene tablets、hypertension,筛选2000—2020年发表的研究复方利血平氨苯蝶啶片的安全性及有效性的随机对照试验。由2位研究员按纳入与排除标准独立筛选文献、提取资料和评价纳入研究的方法学质量后,采用Revman5.4软件进行Meta分析。结果最终纳入7项研究。Meta分析结果显示:在5项研究中,与其他降压药相比,复方利血平氨苯蝶啶片降压总有效率更高(OR=2.23,95%CI:1.32~3.75);不良反应发生率差异无统计学意义(OR=0.91,95%CI:0.68~1.22)。结论复方利血平氨苯蝶啶片治疗原发性高血压较其他降压药物降压效果与安全性均更可靠。

Objective To assess the efficacy and safety of Compound Reserpine and Triamterene tablets.Methods PubMed,Cochrane,Web of Science,CNKI,WanFang Data,and VIP databases were electronically searched to collect ran⁃domized controlled trails(RCTs)on the efficacy and safety of Compound Reserpine and Triamterene tablets from 2000 to 2020.Two reviewers independently screened literature and extracted data.Meta-analysis was performed using Revman 5.4 software.Results A total of 7 RCTs were included.Of which,5 researches showed that,compared with control group,the ef⁃fective rate of Compound Reserpine and Triamterene tablets was higher(OR=2.23,95%CI:1.32 to 3.75).There were no sig⁃nificant differences in the incidence of adverse reactions(OR=0.91,95%CI:0.68 to 1.22).Conclusion The efficacy and safety of Compound Reserpine and Triamterene tablets in the treatment of essential hypertension are reliable compared with oth⁃er antihypertensive drugs.